CliffBio
small molecule

ORGOVYX

RELUGOLIX

Loss of exclusivitySeptember 2037latest FDA-listed patent expiry
CompanySumitomo Pharma America →See this company's full patent-cliff portfolio

Drug detail

Brand nameORGOVYX
Active ingredientRELUGOLIX
Strength120MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2020
Marketing statusRX

Listed patents

PatentExpiresType
12144809September 2037use U-4035
11583526September 2037use U-3020
12336990September 2037use U-3020
12097198September 2037use U-3020
10449191September 2037use U-3020
10786501September 2037use U-3020
12629370September 2037use U-3020
10350170February 2036product
11795178September 2033substance, product
12325714September 2033substance, product
7300935January 2029substance
8058280January 2026substance, product

More from Sumitomo Pharma America

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ORGOVYX patent cliff — loss of exclusivity September 2037 | CliffBio